Recovery incentives program: California's contingency management benefit.

Cocaine Contingency management Methamphetamine Stimulants Treatment

Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 04 05 2023
revised: 06 09 2023
accepted: 13 09 2023
medline: 20 11 2023
pubmed: 18 9 2023
entrez: 17 9 2023
Statut: ppublish

Résumé

The role of methamphetamine and cocaine use in California's drug poisoning (overdose) crisis has dramatically increased in the past five (5) years and has disproportionately affected American Indian, Alaska Native, and Black Californians. No FDA-approved medications currently exist for the treatment of individuals with stimulant use disorder (StimUD). Outside the Veteran's Administration, the Recovery Incentives Program: California's Contingency Management Benefit is the first large scale implementation of contingency management (CM). CM is the behavioral treatment with the most evidence and largest effect sizes for StimUD. The Program uses a CM protocol where participants can receive a maximum of $599 over a six-month period, contingent upon 36 stimulant-negative urine test results. Urine tests are conducted using a set of approved, CLIA-waived, point-of-care urine drug tests (UDTs). To ensure fidelity to the CM protocol and to prevent fraud, waste, and abuse, all aspects of incentive accounting and distribution are managed electronically via a custom-developed software system. Incentive distribution utilizes electronic gift cards. A significant innovation of the project is the conceptualization of the CM Coordinator, a designated and highly trained and supervised individual responsible for all aspects of CM operation in a specific site. The California Department of Health Care Services contracted with UCLA to develop and implement a robust evaluation of the Program; goals include evaluating the effectiveness of real-world implementation and facilitating quality improvement. The project will likely significantly impact the use of CM for StimUD nationally and may well reduce stimulant-related drug poisoning deaths.

Identifiants

pubmed: 37717741
pii: S0091-7435(23)00283-9
doi: 10.1016/j.ypmed.2023.107703
pii:
doi:

Substances chimiques

Methamphetamine 44RAL3456C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107703

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Thomas E Freese (TE)

UCLA Division of Addiction Psychiatry, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, United States of America. Electronic address: tfreese@mednet.ucla.edu.

Beth A Rutkowski (BA)

UCLA Division of Addiction Psychiatry, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, United States of America.

James A Peck (JA)

UCLA Division of Addiction Psychiatry, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, United States of America.

Darren Urada (D)

UCLA Division of Addiction Psychiatry, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, United States of America.

H Westley Clark (HW)

Motivational Incentives Policy Group, United States of America.

Anton Nigusse Bland (AN)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States of America.

Joseph Friedman (J)

Center for Social Medicine and Humanities, University of California, Los Angeles, CA, United States of America.

Richard A Rawson (RA)

UCLA Division of Addiction Psychiatry, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, United States of America; Motivational Incentives Policy Group, United States of America; Vermont Center on Behavior and Health, Center on Rural Addictions, Burlington, VT, United States of America; Department of Psychiatry, University of Vermont, Burlington, VT, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH